Jean-michel Longpre

Sherbrooke, QC J1H5N4, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 59 publications

Improved brain penetration of neurotensin(8-13) via blood-brain barrier shuttle conjugation underlies strong analgesia.

Improved brain penetration of neurotensin(8-13) via blood-brain barrier shuttle conjugation underlies strong analgesia.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: March 05, 2026

Dual-target opioid/neurotensin ligands drive potent and safer analgesia in vivo.

Dual-target opioid/neurotensin ligands drive potent and safer analgesia in vivo.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: November 19, 2025

Structure-activity relationships of contulakin-G: Design, synthesis, and characterization of Thr10 analogs for pain modulation.

Structure-activity relationships of contulakin-G: Design, synthesis, and characterization of Thr10 analogs for pain modulation.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: August 08, 2025

A neurotensin receptor type 1-derived pepducin acts as a biased allosteric modulator to regulate target receptor function.

A neurotensin receptor type 1-derived pepducin acts as a biased allosteric modulator to regulate target receptor function.

Journal: Acta pharmaceutica Sinica. B

Published: August 01, 2025

Docking of virtual libraries identifies small-molecule agonists of neurotensin receptors with analgesic activity.

Docking of virtual libraries identifies small-molecule agonists of neurotensin receptors with analgesic activity.

Journal: Nature communications

Published: April 15, 2025

A lipidated peptide derived from the C-terminal tail of the vasopressin 2 receptor shows promise as a new β-arrestin inhibitor.

A lipidated peptide derived from the C-terminal tail of the vasopressin 2 receptor shows promise as a new β-arrestin inhibitor.

Journal: Pharmacological research

Published: August 23, 2024

Structure-based design of macrocyclic peptides to generate functional antibodies against G protein-coupled receptors.

Structure-based design of macrocyclic peptides to generate functional antibodies against G protein-coupled receptors.

Journal: Nature communications

Published: August 16, 2024

Design, Synthesis, and In Vitro Characterization of Proteolytically-Stable Opioid-Neurotensin Hybrid Peptidomimetics.

Design, Synthesis, and In Vitro Characterization of Proteolytically-Stable Opioid-Neurotensin Hybrid Peptidomimetics.

Journal: ACS pharmacology & translational science

Published: April 23, 2024

Development of Macrocyclic Neurotensin Receptor Type 2 (NTS2) Opioid-Free Analgesics.

Development of Macrocyclic Neurotensin Receptor Type 2 (NTS2) Opioid-Free Analgesics.

Journal: Angewandte Chemie (International ed. in English)

Published: March 27, 2024

Discovery of a CCR2-targeting pepducin therapy for chronic pain.

Discovery of a CCR2-targeting pepducin therapy for chronic pain.

Journal: Pharmacological research

Published: January 26, 2024

Signaling Modulation via Minimal C-Terminal Modifications of Apelin-13.

Signaling Modulation via Minimal C-Terminal Modifications of Apelin-13.

Journal: ACS pharmacology & translational science

Published: November 10, 2022

Ligand-dependent intracellular trafficking of the G protein-coupled P2Y6 receptor.

Ligand-dependent intracellular trafficking of the G protein-coupled P2Y6 receptor.

Journal: Biochimica et biophysica acta. Molecular cell research

Published: September 26, 2022

Showing 1-12 of 59

Last Updated: 09/26/2026